The association between prucalopride efficacy and constipation type

被引:22
|
作者
Jadav, A. M. [1 ]
Mcmullin, C. M. [1 ]
Smith, J. [1 ]
Chapple, K. [1 ]
Brown, S. R. [1 ,2 ]
机构
[1] No Gen Hosp, Colorectal Surg Unit, Sheffield S5 7AU, S Yorkshire, England
[2] No Gen Hosp, Dept Surg, Sheffield S5 7AU, S Yorkshire, England
关键词
Constipation; Prucalopride; Obstructed defaecation syndrome; Slow transit constipation; Constipation-predominant irritable bowel syndrome; LAPAROSCOPIC VENTRAL RECTOPEXY; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; RECTAL PROLAPSE; EPIDEMIOLOGY; TEGASEROD;
D O I
10.1007/s10151-013-1017-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Prucalopride is a selective serotonin receptor agonist with prokinetic activity, indicated for women with chronic constipation in whom laxatives have failed to provide adequate relief. Data suggests an improvement in about 50 % of such patients but whether the therapeutic effect is on patients with slow transit constipation (STC) and/or obstructed defaecation syndrome (ODS), or even those with constipation-predominant irritable bowel syndrome (IBS-C) is unknown. We therefore assessed whether there is any association between prucalopride efficacy and constipation type. All patients receiving prucalopride between June 2010 and April 2012 at our institution were identified, and data analysed following a 4-week "test" period. Patients were sub-grouped as those suffering with ODS, STC, mixed (ODS and STC) or IBS-C based on symptomatology and investigations. Subjective assessment of patient satisfaction and continuation of medication were taken as positive outcomes and analysed for each sub-type along with any side effects. Sixty-nine patients met our criteria. Data were available for 59 women (median age 46 years, range 17-79 years). Sixty-five per cent of prescriptions came from colorectal surgeons. Overall, 25 out of 59 (42 %) patients improved, according to our criteria, after the 4-week trial period. Seventeen patients (29 %) had ODS, 26 (44 %) had STC, 7 (12 %) had mixed symptoms and 9 (15 %) had IBS-C. At 4 weeks, 10 out of 17 patients (59 %) with ODS had improved compared with 4 out of 9 patients (44 %) with IBS-C, 3 out of 7 patients (43 %) with mixed symptoms and 8 out of 26 (31 %) patients with STC. The underlying disorder did not predict whether or not a patient responded to the 4-week trial period (p = 0.32). Nine patients (15 %) experienced side effects that precluded further use. Patients with all categories of constipation may respond to prucalopride. A trial regime may be indicated regardless of the aetiology of the constipation.
引用
收藏
页码:555 / 559
页数:5
相关论文
共 50 条
  • [1] The association between prucalopride efficacy and constipation type
    A. M. Jadav
    C. M. Mcmullin
    J. Smith
    K. Chapple
    S. R. Brown
    Techniques in Coloproctology, 2013, 17 : 555 - 559
  • [2] An update on prucalopride in the treatment of chronic constipation
    Omer, Anam
    Quigley, Eamonn M. M.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (11) : 877 - 887
  • [3] Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials
    Camilleri, Michael
    Piessevaux, Hubert
    Yiannakou, Yan
    Tack, Jan
    Kerstens, Rene
    Quigley, Eamonn M. M.
    Ke, MeiYun
    Da Silva, Susana
    Levine, Amy
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (08) : 2357 - 2372
  • [4] An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation
    Daniali, Marzieh
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (17) : 2073 - 2080
  • [5] Effect of prucalopride on symptoms of chronic constipation
    Tack, J.
    Stanghellini, V.
    Dubois, D.
    Joseph, A.
    Vandeplassche, L.
    Kerstens, R.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (01) : 21 - 27
  • [6] Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation
    Din, Asim Tameez Ud
    Khan, Ameer H.
    Bajwa, Hamza
    Maqsood, Muhammad Haisum
    Malik, Mustafa N.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (04)
  • [7] Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation
    Tack, Jan
    Corsetti, Maura
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (10) : 1327 - 1335
  • [8] Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury
    Krogh, K
    Jensen, MB
    Gandrup, P
    Laurberg, S
    Nilsson, J
    Kerstens, R
    De Pauw, M
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (04) : 431 - 436
  • [9] Prucalopride for constipation
    Camilleri, Michael
    Deiteren, Annemie
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (03) : 451 - 461
  • [10] A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation
    Mueller-Lissner, S.
    Rykx, A.
    Kerstens, R.
    Vandeplassche, L.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2010, 22 (09) : 991 - +